Sign in or create an account to add this stock to your watchlist.
About Cesca Therapeutics (NASDAQ:KOOL)
Cesca Therapeutics, Inc. engages in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It operates through the Clinical Development Division and Device Division business segments. The Clinical Development Division segment involves in developing autologous stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology, and orthopedic markets. The Device Division segment includes development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The company was founded by Philip H. Coelho in 1986 and is headquartered in Rancho Cordova, CA.
Industry, Sector and Symbol
Industry Laboratory apparatus & furniture
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KOOL
CUSIPN/A
Phone916-858-5100
Debt
Debt-to-Equity Ratio0.23
Current Ratio1.61
Quick Ratio0.79
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$14.52 million
Price / Sales0.42
Cash Flow$0.2190 per share
Price / Cash2.42
Book Value$3.11 per share
Price / Book0.17
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-29,090,000.00
Net Margins-56.21%
Return on Equity-20.31%
Return on Assets-12.98%
Miscellaneous
Employees70
Outstanding Shares11,480,000
Cesca Therapeutics (NASDAQ:KOOL) Frequently Asked Questions
What is Cesca Therapeutics' stock symbol?
Cesca Therapeutics trades on the NASDAQ under the ticker symbol "KOOL."
How were Cesca Therapeutics' earnings last quarter?
Cesca Therapeutics Inc (NASDAQ:KOOL) issued its quarterly earnings results on Thursday, March, 22nd. The biotechnology company reported $0.01 EPS for the quarter. The biotechnology company had revenue of $2.94 million for the quarter. Cesca Therapeutics had a negative return on equity of 20.31% and a negative net margin of 56.21%. View Cesca Therapeutics' Earnings History.
When is Cesca Therapeutics' next earnings date?
Who are some of Cesca Therapeutics' key competitors?
Some companies that are related to Cesca Therapeutics include Dynatronics (DYNT), Liberty Biopharma (LTY), Akers Biosciences (AKR), PAVmed (PAVM), Agile Therapeutics (AGRX), Parallax Health Sciences (PRLX), Cyanotech (CYAN), Innovus Pharmaceuticals (INNV), Vistagen Therapeutics (VTGN), Burcon Nutrascience (BU), Fibrocell (FCSC), ContraVir Pharmaceuticals (CTRV), ChroMedX (CHXIF), Akari Therapeutics (AKTX) and Aethlon Medical (AEMD).
Who are Cesca Therapeutics' key executives?
Cesca Therapeutics' management team includes the folowing people:
- Xiao Chun Xu, Chairman, President & Chief Executive Officer
- Vivian H. Liu, Chief Operating Officer & Director
- Jeffery Cauble, Principal Financial & Accounting Officer
- Philip H. Coelho, Chief Technology Officer
- Dalip Sethi, Senior Director-Research & Development
Has Cesca Therapeutics been receiving favorable news coverage?
Media stories about KOOL stock have trended somewhat negative recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Cesca Therapeutics earned a news sentiment score of 0.00 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 47.98 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of Cesca Therapeutics?
Shares of KOOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cesca Therapeutics' stock price today?
One share of KOOL stock can currently be purchased for approximately $0.53.
How big of a company is Cesca Therapeutics?
Cesca Therapeutics has a market capitalization of $5.97 million and generates $14.52 million in revenue each year. Cesca Therapeutics employs 70 workers across the globe.
How can I contact Cesca Therapeutics?
Cesca Therapeutics' mailing address is 2711 CITRUS ROAD, RANCHO CORDOVA CA, 95742. The biotechnology company can be reached via phone at 916-858-5100 or via email at [email protected]
MarketBeat Community Rating for Cesca Therapeutics (KOOL)
MarketBeat's community ratings are surveys of what our community members think about Cesca Therapeutics and other stocks. Vote "Outperform" if you believe KOOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KOOL will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cesca Therapeutics (NASDAQ:KOOL) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | N/A | Hold | Hold | Hold |
| Consensus Rating Score: | N/A | 2.00 | 2.00 | 2.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | N/A |
| Price Target Upside: | N/A | N/A | N/A | N/A |
Cesca Therapeutics (NASDAQ:KOOL) Consensus Price Target History
Cesca Therapeutics (NASDAQ:KOOL) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/12/2017 | Maxim Group | Reiterated Rating | Hold | | Low |  |
(Data available from 5/22/2016 forward)
Cesca Therapeutics (NASDAQ:KOOL) Earnings History and Estimates Chart
Cesca Therapeutics (NASDAQ KOOL) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 9/18/2018 | | | | | | | | |
| 5/14/2018 | Q1 2018 | | ($0.27) | | $1.87 million | View | Listen | |
| 3/22/2018 | Q2 2018 | | $0.01 | | $2.94 million | View | N/A | |
| 11/14/2017 | Q1 2018 | | ($0.24) | | $3.07 million | View | N/A | |
| 9/19/2017 | Q4 2017 | | ($0.01) | | $3.50 million | View | N/A | |
| 5/11/2017 | Q3 2017 | | ($0.21) | | $3.25 million | View | N/A | |
| 2/13/2017 | Q2 2017 | | ($0.35) | | $4.01 million | View | N/A | |
| 11/17/2016 | Q1 2017 | | ($0.34) | | $3.77 million | View | N/A | |
| 9/20/2016 | Q4 2016 | | ($1.01) | | $2.98 million | View | N/A | |
| 5/13/2016 | Q3 2016 | | ($1.42) | | $2.83 million | View | N/A | |
| 2/16/2016 | Q216 | ($0.07) | ($0.02) | $4.32 million | $3.29 million | View | Listen | |
| 11/16/2015 | Q116 | ($0.06) | ($0.08) | $3.71 million | $2.80 million | View | Listen | |
| 9/17/2015 | Q415 | ($0.11) | ($0.06) | $4.08 million | $3.70 million | View | Listen | |
| 6/23/2015 | Q315 | ($0.08) | ($0.12) | $4.69 million | $4.04 million | View | Listen | |
| 2/12/2015 | Q215 | ($0.08) | ($0.11) | $4.08 million | $4.60 million | View | N/A | |
| 11/13/2014 | Q115 | | ($0.08) | $3.60 million | $3.70 million | View | N/A | |
| 9/29/2014 | Q4 2014 | | ($1.60) | | $3.84 million | View | N/A | |
| 5/15/2014 | Q3 2014 | ($0.05) | ($0.07) | | $4.04 million | View | N/A | |
| 2/14/2014 | Q214 | | ($0.10) | $4.80 million | $4.50 million | View | N/A | |
| 11/14/2013 | Q1 | | ($0.14) | | $3.64 million | View | Listen | |
| 8/29/2013 | Q4 2013 | | ($0.14) | $4.50 million | $4.10 million | View | N/A | |
| 5/14/2013 | Q3 2013 | | ($1.40) | | $4.89 million | View | N/A | |
| 2/12/2013 | Q2 2013 | | ($0.60) | | | View | N/A | |
| 11/13/2012 | Q113 | | $0.06 | $4.90 million | $4.10 million | View | N/A | |
| 9/20/2012 | Q4 2012 | | ($0.90) | | | View | N/A | |
| 5/10/2012 | Q3 2012 | | ($2.14) | | | View | N/A | |
| 2/9/2012 | Q2 2012 | | ($1.56) | | | View | N/A | |
| 11/10/2011 | Q1 2012 | | ($1.48) | | | View | N/A | |
| 9/12/2011 | Q4 2011 | | ($1.42) | | | View | N/A | |
| 5/5/2011 | Q3 2011 | | ($1.14) | | | View | N/A | |
| 2/10/2011 | Q2 2011 | $0.20 | ($0.68) | | | View | N/A | |
| 9/14/2010 | Q4 2010 | ($0.80) | ($0.24) | | | View | N/A | |
| 5/6/2010 | Q3 2010 | | ($1.92) | | | View | N/A | |
| 2/4/2010 | Q2 2010 | ($1.60) | ($2.08) | | | View | N/A | |
| 11/5/2009 | Q1 2010 | | ($3.12) | | | View | N/A | |
| 9/9/2009 | Q4 2009 | ($0.80) | ($1.44) | | | View | N/A | |
| 5/6/2009 | Q3 2009 | ($1.60) | ($1.52) | | | View | N/A | |
| 2/4/2009 | Q2 2009 | ($3.20) | ($1.84) | | | View | N/A | |
| 9/9/2008 | Q4 2008 | ($2.40) | ($3.52) | | | View | N/A | |
| 5/7/2008 | Q3 2008 | ($1.60) | ($3.84) | | | View | N/A | |
| 2/6/2008 | Q2 2008 | | ($2.48) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Cesca Therapeutics (NASDAQ:KOOL) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cesca Therapeutics (NASDAQ KOOL) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 2.41%
Cesca Therapeutics (NASDAQ KOOL) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/26/2016 | (Hong Kong) Ltd Boyalife | Major Shareholder | Buy | 6,102,942 | $2.52 | $15,379,413.84 | 6,838,237 | |
| 11/10/2015 | Kenneth Harris | Director | Sell | 80,858 | $0.60 | $48,514.80 | 4,490,410 | |
| 11/9/2015 | Kenneth Harris | Director | Sell | 48,468 | $0.60 | $29,080.80 | 4,490,410 | |
| 11/6/2015 | Kenneth Harris | Director | Sell | 30,190 | $0.60 | $18,114.00 | 4,490,410 | |
| 11/3/2015 | Kenneth Harris | Director | Sell | 10,510 | $0.60 | $6,306.00 | 4,571,268 | |
| 11/2/2015 | Kenneth Harris | Director | Sell | 5,700 | $0.60 | $3,420.00 | 4,571,268 | |
| 10/29/2015 | Kenneth Harris | Director | Sell | 8,632 | $0.60 | $5,179.20 | 4,581,778 | |
| 9/2/2015 | Matthew T. Plavan | CEO | Sell | 17,271 | $0.68 | $11,744.28 | 245,066 | |
(Data available from 1/1/2013 forward)
Cesca Therapeutics (NASDAQ KOOL) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Cesca Therapeutics raises $5.5 million in stock offering
www.bizjournals.com - May 22 at 9:09 AM |
 | Cesca Announces Closing of $5.5 Million Public Offering
finance.yahoo.com - May 18 at 4:47 PM |
| Today’s Research Reports on Stocks to Watch: Abaxis, Inc. and Cesca Therapeutics
finance.yahoo.com - May 17 at 9:29 AM |
 | Cesca Therapeutics (KOOL) Prices $5.5 Million Public Offering of Common Stock, Warrants
www.streetinsider.com - May 16 at 4:39 PM |
 | Cesca Prices $5.5 Million Public Offering
feeds.benzinga.com - May 16 at 12:55 PM |
 | Cesca Therapeutics Inc. (KOOL) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 9:47 AM |
| Cesca Therapeutics Announces First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 14 at 4:39 PM |
 | Cesca Therapeutics (KOOL) Posts Quarterly Earnings Results
www.americanbankingnews.com - May 14 at 10:18 AM |
| Cesca Therapeutics to Announce Financial Results for the First Quarter Ended March 31, 2018 and Host Conference Call on May 14
finance.yahoo.com - May 9 at 9:20 AM |
| Cesca Therapeutics Inc. Presents New Data on its Proprietary X-Series™ Cellular Processing Systems
feeds.benzinga.com - May 4 at 5:32 PM |
| Cesca Therapeutics (KOOL) Lifted to Hold at ValuEngine
www.americanbankingnews.com - May 3 at 11:51 PM |
| Cesca Therapeutics (KOOL) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 2 at 3:50 AM |
| Cesca Therapeutics (KOOL) and H2O Innovation (HEOFF) Critical Contrast
www.americanbankingnews.com - April 29 at 7:55 AM |
| Comparing Cesca Therapeutics (KOOL) and H2O Innovation (HEOFF)
www.americanbankingnews.com - April 27 at 8:52 AM |
| Contrasting Cesca Therapeutics (KOOL) & H2O Innovation (HEOFF)
www.americanbankingnews.com - April 26 at 12:08 PM |
| Cesca Therapeutics Inc. to Exhibit at Several Upcoming Cell Therapy Conferences
finance.yahoo.com - April 25 at 9:21 AM |
| Cesca Therapeutics Announces Evaluation Agreement With The University Of North Carolina Lineberger Advanced Cellular Therapeutics Facility for X-Series™ Products That Provide Automated, Closed System Cellular Processing
finance.yahoo.com - April 24 at 4:49 PM |
 | Cesca Therapeutics Announces Evaluation Agreement With The University Of North Carolina Lineberger
www.nasdaq.com - April 24 at 9:15 AM |
| Cesca Therapeutics (KOOL) Raised to Hold at ValuEngine
www.americanbankingnews.com - April 19 at 2:58 PM |
| Has Cesca Therapeutics Inc (NASDAQ:KOOL) Improved Earnings Growth In Recent Times?
finance.yahoo.com - April 17 at 5:02 PM |
| Cesca Therapeutics Announces First Evaluation Agreement With a Leading U.S. Academic Research Institution for X-Series™ Products That Provide Automated, Closed System Cellular Processing
finance.yahoo.com - April 17 at 9:39 AM |
| Critical Analysis: H2O Innovation (HEOFF) and Cesca Therapeutics (KOOL)
www.americanbankingnews.com - April 16 at 7:41 PM |
| ValuEngine Lowers Cesca Therapeutics (KOOL) to Sell
www.americanbankingnews.com - April 16 at 7:35 PM |
| Head to Head Analysis: H2O Innovation (HEOFF) & Cesca Therapeutics (KOOL)
www.americanbankingnews.com - April 12 at 9:51 AM |
| Cesca Therapeutics (KOOL) vs. H2O Innovation (HEOFF) Critical Survey
www.americanbankingnews.com - April 12 at 5:23 AM |
| Cesca Therapeutics (KOOL) & H2O Innovation (HEOFF) Head-To-Head Survey
www.americanbankingnews.com - April 9 at 7:14 AM |
| Analyzing H2O Innovation (HEOFF) and Cesca Therapeutics (KOOL)
www.americanbankingnews.com - April 7 at 11:16 AM |
| Reviewing H2O Innovation (HEOFF) & Cesca Therapeutics (KOOL)
www.americanbankingnews.com - April 3 at 9:55 AM |
| Cesca Therapeutics (KOOL) Says Two Abstracts Accepted for Poster Presentation at ISCT
www.streetinsider.com - April 3 at 9:35 AM |
| Cesca Therapeutics Inc. Announces Release of X-Mini™ Cell Selection Kit for the CAR-T Research Market
finance.yahoo.com - April 3 at 9:35 AM |
| Comparing H2O Innovation (HEOFF) & Cesca Therapeutics (KOOL)
www.americanbankingnews.com - April 1 at 9:19 AM |
| Cesca Therapeutics Inc. Announces Two Abstracts Accepted for Poster Presentation at the International Society for Cellular Therapy (ISCT) 2018 Annual Meeting
finance.yahoo.com - March 28 at 9:33 AM |
| Cesca raising $1.4 million in direct offering of stock
finance.yahoo.com - March 27 at 9:43 AM |
| Cesca inks direct placement of stock and warrants; shares down 17%
seekingalpha.com - March 26 at 4:28 PM |
| Cesca Therapeutics Announces Financial Results for the Transition Period July 1, 2017 to December 31, 2017, and Provides Corporate Update
finance.yahoo.com - March 22 at 4:35 PM |
| Cesca Therapeutics (KOOL) Expands CAR-TXpress IP Portfolio with Filing of New Patent Covering Cell Activation & Transduction
www.streetinsider.com - March 19 at 9:29 AM |
| Cesca Therapeutics Expands CAR-TXpress™ Intellectual Property Portfolio with Filing of New Patent Covering Cell Activation & Transduction
finance.yahoo.com - March 19 at 9:29 AM |
| Contrasting Cesca Therapeutics (KOOL) and Kadmon (KDMN)
www.americanbankingnews.com - March 16 at 7:24 PM |
| Cesca Therapeutics (KOOL) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - March 16 at 10:02 AM |
 | Cesca Flat on Expansion
www.baystreet.ca - March 15 at 9:10 AM |
| Cesca Therapeutics to Announce Financial Results for the Transition Period From July 1, 2017 to December 31, 2017 on March 22
finance.yahoo.com - March 15 at 9:10 AM |
| Cesca’s Device Subsidiary, ThermoGenesis, Expands into CAR-T Related Contract Development and Manufacturing (CDMO) Services
finance.yahoo.com - March 14 at 10:16 AM |
| Cesca Therapeutics Inc. to Present at BIO-Europe Spring® 2018
finance.yahoo.com - March 6 at 9:10 AM |
| Comparing Cesca Therapeutics (KOOL) and Cardiome Pharma (CRME)
www.americanbankingnews.com - March 4 at 3:20 PM |
| Analyzing Kadmon (KDMN) and Cesca Therapeutics (KOOL)
www.americanbankingnews.com - February 28 at 1:30 AM |
| Cesca Therapeutics Inc. Announces Commercial Launch of AXP® II System for Advanced Cord Blood Processing
finance.yahoo.com - February 26 at 9:11 AM |
| Comparing Kadmon (KDMN) and Cesca Therapeutics (KOOL)
www.americanbankingnews.com - February 26 at 1:34 AM |
| Cesca Therapeutics Inc (NASDAQ:KOOL) And The Healthcare Industry Prospect For 2018
finance.yahoo.com - February 9 at 5:08 PM |
| Cesca Therapeutics Inc. to Present at the BIO CEO & Investor Conference on Monday, February 12, 2018
finance.yahoo.com - February 5 at 9:13 AM |
| Cesca Therapeutics (KOOL) versus Vitae Pharmaceuticals (VTAE) Critical Survey
www.americanbankingnews.com - January 17 at 11:40 AM |
Cesca Therapeutics (NASDAQ:KOOL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cesca Therapeutics (NASDAQ:KOOL) Income Statement, Balance Sheet and Cash Flow Statement
Cesca Therapeutics (NASDAQ KOOL) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
